MarketResearchReports.biz has added a new research report to its repository. The report, titled “Global Alpha-1 Antitrypsin Drugs Market 2016-2020”, offers a comprehensive study on the global alpha-1 antitrypsin drugs market and analyzes the key factors affecting the growth of the market. The report projects the global alpha-1 antitrypsin drugs market to robustly expand at a CAGR of 35.42% during the period between 2016 and 2020. The existing value chain in the market has been analyzed in the report with emphasis on the upstream and downstream components. The report studies the overall alpha-1 antitrypsin drugs market on the basis of route of administration and regions. Profiles of some of the key players in the market have been included in the report along with insightful information about them.
Alpha-1 antitrypsin is a glycoprotein produced in the liver, also known as alpha-1 protease inhibitor (A1PI), this glycoprotein inactivates enzymes such as elastase that breaks down proteins during inflammation caused due to some injury. Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition where the levels of alpha-1 antitrypsin decline in blood. This leads to various liver and respiratory diseases and skin infections. This disease gets passed from one generation to other through mutated genes. To treat this genetic condition, augmentation therapy is usually prescribed to maintain levels of alpha-1 antitrypsin in blood. In this therapy, drugs derived from human plasma are administered.
The report states that the improved diagnosis of alpha-1 antitrypsin deficiency has boosted the growth of the global alpha-1 antitrypsin drugs market. However, limited plasma fractionation capacity might restrain the market’s growth during the forecast horizon. The overall market has a huge opportunity to grow with the growing awareness about augmentation therapy.
On the basis of route of administration, the report segments the global alpha-1 antitrypsin drugs market into inhalation and parenteral. The number of alpha-1 antitrypsin drugs administered through the parenteral route is higher than the inhalation route as parenteral route offers benefits such as ease of drug administration and prevents the first-pass metabolism.
The report studies the global alpha-1 antitrypsin drugs market across some of the key regions such as the Americas, APAC, and EMEA. The report analyzes the impact of various micro- and macro-economic factors determining the growth of the market in each of these regions.
Describing the competitive landscape, the report profiles some of the key players in the global alpha-1 antitrypsin drugs market such as CSL Behring, Baxter International, Kamada, Grifols, ProMetic Life Sciences, Laboratoire franais du Fractionnement et des Biotechnologies, ProBioGen, Chiesi, Curaxys, Biogen, Abeona Therapeutics, Applied Genetic Technologies, Alnylam Pharmaceuticals, Arrowhead Research, and Baxalta. The report also provides insightful information about the key players including their company overview, revenue, financial overview, regional presence, product specifications, and recent developments.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com